Genome-epigenome interactions in cancer.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or original data.
PubMed 17613554 · doi:10.1093/hmg/ddm073
What was done
The authors reviewed the cooperation between genetic mutations and epigenetic alterations (such as aberrant DNA methylation) in tumor initiation and progression. The review evaluated emerging high-throughput technologies capable of mapping cancer methylomes across 28 million CpG dinucleotides alongside genomic sequencing data to discuss their integrated application in cancer gene discovery and therapeutic development.
What was found
The abstract reports no quantitative experimental results or pooled numerical data. It discusses conceptual frameworks showing that epigenetic alterations alone can induce tumorigenesis or modify tumor type and incidence in genetic cancer models, and argues that full-scale multi-omic integration is required to model human tumorigenesis accurately.
Why it matters
It highlights that evaluating genetic mutations in isolation creates a biased understanding of cancer biology, arguing for integrated genomic and epigenomic profiling to improve biomarker discovery and targeted therapy design.
Limits
This is a narrative review presenting theoretical models and technological perspectives rather than a systematic review or original empirical study. No primary clinical data, experimental controls, or quantitative syntheses are reported in the abstract.
Cited by
- context The human genome contains approximately 28 million cytosine locations, roughly a quarter of which change methylation status with age.